Company
Geron Corporation
Headquarters: Menlo Park, CA, United States
Employees: 69
CEO: Dr. John A. Scarlett M.D.
Market Cap
$910.8 Million
USD as of July 1, 2025
Geron Corporation Categories
United States Healthcare BiotechnologyUnited States Healthcare United States Biotechnology
Top Competitors by Market Capitalization
Industry: Biotechnology
| Company | Market Cap (USD) |
|---|---|
| Novo Nordisk | $309.91 B |
| Vertex Pharmaceuticals Incorporated | $117.36 B |
| CSL Limited | $95.75 B |
| Regeneron Pharmaceuticals, Inc. | $59.14 B |
| Marinomed Biotech AG | $58.56 B |
Sector:
| Company | Market Cap (USD) |
|---|---|
| Lilly | $699.59 B |
| Johnson & Johnson | $374.29 B |
| AbbVie | $336.94 B |
| Novo Nordisk | $309.91 B |
| UnitedHealth Group | $279.90 B |
Detailed Description
Geron Corporation, a late-stage clinical biopharmaceutical company, focuses on the development and commercialization of therapeutics for myeloid hematologic malignancies. It develops imetelstat, a telomerase inhibitor that is in Phase 3 clinical trials, which inhibits the uncontrolled proliferation of malignant stem and progenitor cells in hematologic myeloid malignancies for the treatment of low or intermediate-1 risk myelodysplastic syndromes and intermediate-2 or high-risk myelofibrosis. The company was incorporated in 1990 and is headquartered in Foster City, California.
Financials
| Last Financial Reports Date | March 31, 2025 |
| Revenue TTM | $116.3 M |
| EBITDA | $-133,736,000 |
| Gross Profit TTM | $9.4 M |
| Profit Margin | -119.54% |
| Operating Margin | -42.18% |
| Quarterly Revenue Growth | 12927.30% |
Stocks & Indices
Geron Corporation has the following listings and related stock indices.
Stock: NASDAQ: GERN wb_incandescent
Stock: FSX: GON wb_incandescent